Veloxis Pharmaceuticals A/S has decided to close its office in Hørsholm, Denmark, and move all activities to the US where most of the company’s current activities is already located.
The process is expected to be completed during the second half of 2016.
“As most of the company’s activities are located in the U.S. combined with the launch of Envarsus XR in the US through our own sales force we believe a consolidation of activities will further strengthen the company to meet new opportunities and to further grow our business.” said Craig Collard, CEO.
Veloxis will continue to be a Danish company listed on Nasdaq Copenhagen A/S.
Photo Stepan Popov/istockphoto